Fulcrum Therapeutics (FULC) Operating Income (2020 - 2025)
Historic Operating Income for Fulcrum Therapeutics (FULC) over the last 6 years, with Q3 2025 value amounting to -$21.9 million.
- Fulcrum Therapeutics' Operating Income rose 1300.64% to -$21.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$86.2 million, marking a year-over-year decrease of 18308.6%. This contributed to the annual value of -$21.9 million for FY2024, which is 8021.31% up from last year.
- Per Fulcrum Therapeutics' latest filing, its Operating Income stood at -$21.9 million for Q3 2025, which was up 1300.64% from -$19.8 million recorded in Q2 2025.
- Over the past 5 years, Fulcrum Therapeutics' Operating Income peaked at $52.5 million during Q2 2024, and registered a low of -$34.2 million during Q2 2022.
- Its 5-year average for Operating Income is -$20.4 million, with a median of -$24.7 million in 2022.
- Its Operating Income has fluctuated over the past 5 years, first surged by 29233.48% in 2024, then tumbled by 13774.86% in 2025.
- Fulcrum Therapeutics' Operating Income (Quarter) stood at -$23.6 million in 2021, then fell by 18.74% to -$28.0 million in 2022, then decreased by 0.07% to -$28.0 million in 2023, then surged by 30.59% to -$19.4 million in 2024, then dropped by 12.5% to -$21.9 million in 2025.
- Its Operating Income stands at -$21.9 million for Q3 2025, versus -$19.8 million for Q2 2025 and -$19.4 million for Q4 2024.